Fig. 5: Enhanced in vivo growth of CD38^KO CTCL cells compared to CD38^WT cells.

A Intravenously engrafted H9 CD38^WT and H9 CD38^KO CTCL cell lines in immunodeficient NOD Rag^−/−γc^−/− (NRG) mice were monitored over time using an In Vivo Imaging System (IVIS; Perkins-Elmer) and representative images from day 18 post-engraftment are shown. B Quantification of the tumor cell luminescent intensity signal as measured by total flux (photons/second) in the CD38^WT and CD38^KO intravenous cohorts (CD38^WT = 2.2e8 photons/sec average total flux, N = 7; CD38^KO = 1e9 photons/sec, N = 5; p = 0.003 by Mann–Whitney test). C Flow cytometry analysis of human CD45+ tumor cells harvested the bone marrow of NRG mice post IV-engraftment and expansion of H9 CD38^WT and H9 CD38^KO luciferase CTCL cell lines. D IVIS images of tumor signal at 19 days post-subcutaneous flank engraftment of H9 CD38^WT and H9 CD38^KO luciferase CTCL cell lines in NRG mice. E Tumor cell burden as measured by total flux of subcutaneous CD38^WT and CD38^KO cells (CD38^WT = 1.01e8 photons/sec average total flux, N = 7; CD38^KO = 6.01e9 photons/sec, N = 8; p < 0.0001 by unpaired t test). F Flank tumors were dissected and photographed on a grossing board. Image J was used to measure tumor size in mm² (p = 0.01 by Mann–Whitney test). G Dissected tumors were formalin fixed and paraffin embedded before being stained for human CD38 and imaged at original magnification x4 and x20 on a Cytation5 imager with Gen5 software.